Biosion
Biosion's Overview
Biosion is a global, clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative antibody-based therapies for patients with immune and oncology diseases. Leveraging its proprietary SynTracer® high-throughput antibody discovery platform and other advanced technologies, Biosion is building a robust pipeline of potential first-in-class or best-in-class drug candidates. The company has operations in the U.S., China, and Australia, focusing on advancing its therapeutic programs through clinical development and towards market.
Where is Biosion's Headquarters?
HQ Function
Serves as the company's U.S. operational base, supporting global clinical development, business development, regulatory affairs, and strategic partnerships in North America.
Notable Features:
The facility is part of the University of Delaware's STAR Campus, offering modern laboratory and office spaces designed to foster innovation and collaboration in life sciences research.
Work Culture:
Fosters a dynamic, innovative, and collaborative environment focused on scientific excellence, rapid advancement of therapeutic programs, and ultimately improving patient care.
HQ Significance:
The Delaware location provides access to a rich talent pool, proximity to leading academic and medical institutions, and a supportive ecosystem for biotech growth. It strengthens Biosion's presence in the key U.S. market for clinical trials and commercialization.
Values Reflected in HQ: The choice of a modern, collaborative space in a key U.S. biotech hub reflects Biosion's commitment to innovation, scientific excellence, and strategic global growth.
Location:
Biosion supports its global operations through a network of R&D centers and offices in the United States (Delaware, Texas), China (Nanjing, Guangzhou), and Australia (Sydney). These sites collaboratively drive drug discovery, preclinical and clinical development, CMC activities, regulatory affairs, and strategic partnerships across key international markets, enabling a 24/7 approach to innovation and development.
Street Address:
300 Christina Parkway, Suite 100
City:
Newark
State/Province:
Delaware
Country:
USA
Biosion's Global Presence
Nanjing, Jiangsu, China
Address: Building D, No.3-1 Xinjinhu Road, Jiangbei New District, Nanjing, Jiangsu, 210000, P. R. China
Drives innovation and clinical execution in China and the broader Asian market, leveraging local talent, manufacturing capabilities, and research infrastructure. Serves as Biosion (China) Co., Ltd. headquarters.
Guangzhou, Guangdong, China
Address: Building B7, No.18 Life Science Park Road, Sino-Singapore Guangzhou Knowledge City, Guangzhou, Guangdong, 510555, P. R. China
Strengthens Biosion's research capabilities in Southern China's dynamic biotech cluster, fostering the discovery of novel therapeutic antibodies and pre-clinical candidates.
Sydney, NSW, Australia
Address: Level 36, Governor Phillip Tower, 1 Farrer Place, Sydney, NSW 2000, Australia
Manages and coordinates clinical studies in Australia, taking advantage of the favorable R&D tax incentives and efficient clinical trial approval pathways.
Houston, Texas, USA
Address: Specific address not publicly detailed; operations may be co-located or managed by key personnel in the region.
Enhances U.S. operational capabilities, possibly focusing on specific therapeutic areas or collaborations within the Texas Medical Center and biotech ecosystem.
Buying Intent Signals for Biosion
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Biosion
As of April 2025, Biosion' leadership includes:
Investors of Biosion
Biosion has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Biosion has strengthened its executive team in the past 12 months with key strategic hires in R&D leadership and finance. Notable appointments include Dr. Rakesh Dixit as Global Head of Biologics Safety Assessment and Vincent Liu as CFO, indicating a continued focus on advancing its pipeline and robust financial strategy. No major executive departures have been publicly announced during this period.
New Appointments:
Technology (Tech Stack) used by Biosion
Discover the tools Biosion uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Biosion Email Formats and Examples
Biosion appears to utilize multiple email formats for its employees. A commonly observed and confirmed format in public communications is [first].[last]@biosion.com. Users may also encounter other standard corporate email patterns.
[first].[last]@biosion.com
Format
jane.doe@biosion.com
Example
85%
Success rate
News and media
Biosion Website / PR Newswire • February 19, 2024
Biosion Announces NMPA Acceptance of Investigational New Drug (IND) Application for BSI-082, an Anti-Siglec-15 Monoclonal Antibody
Biosion announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has accepted its Investigational New Drug (IND) application for BSI-082, an anti-Siglec-15 monoclonal antibody, for the treatment of advanced solid tumors. This marks a significant step in the clinical development of this novel immunotherapy candidate....more
Biosion Website / PR Newswire • November 2, 2023
Biosion Announces Appointment of Rakesh Dixit, Ph.D., DABT as Global Head of Biologics Safety Assessment, SVP R&D
Biosion appointed Dr. Rakesh Dixit, a distinguished expert in toxicology and biologics safety, as its Global Head of Biologics Safety Assessment and Senior Vice President of R&D. Dr. Dixit's extensive experience is expected to further strengthen Biosion's research and development leadership....more
Biosion Website / Business Wire • September 13, 2023
Biosion Announces Appointment of Vincent Liu, MBA as Chief Financial Officer
Biosion appointed Vincent Liu as its Chief Financial Officer. Mr. Liu brings over 20 years of experience in finance and capital markets within the biotech industry and will lead Biosion's financial strategy and operations....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Biosion, are just a search away.